The European Bank for Reconstruction and Development (EBRD) has fully exited its 8.8% stake in Ibnsina Pharma on the Egyptian Exchange. Initially acquiring a 20% stake in 2015, the EBRD supported the company’s growth into Egypt’s leading pharmaceutical distributor. CEO Omar Abdel Gawad praised the partnership, which was crucial for their expansion. EBRD’s Hassan Massoud highlighted the successful exit amid Egypt’s challenging economy, noting the EGX’s reliability for private equity exits. Since 2012, the EBRD has invested over €13.8 billion in 196 projects in Egypt, focusing on various sectors, including healthcare and renewable energy.